格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究  

Efficacy and safety of glecaprevir/pibrentasvir in treating patients with HCV mono-infection and HIV/HCV co-infection

作　　者：曹汴川 刘梅 丁苹 汤玲毓 郭明贤 周仙 袁天茹 严一凯 黄富礼 黄永茂 Cao Bianchuan;Liu Mei;Ding Ping(Department of Infectious Diseases,Affiliated Hospital,Southwest Medical University,Luzhou 646000,Sichuan Province,China)

机构地区：[1]西南医科大学附属医院感染病科,四川省泸州市646000 [2]四川省凉山彝族自治州越西县第一人民医院抗病毒治疗中心 [3]四川省德阳市第六人民医院药剂科

出　　处：《实用肝脏病杂志》2023年第6期801-804,共4页Journal of Practical Hepatology

基　　金：四川省科技厅科研课题(编号:2020YFS0514)。

摘　　要：目的评估应用格卡瑞韦/哌仑他韦治疗丙型肝炎病毒(HCV)感染和人类免疫缺陷病毒(HIV)合并HCV感染者的疗效及安全性。方法2021年4月~2021年12月凉山彝族自治州越西县第一人民医院诊治的HCV感染者25例和HIV合并HCV感染者27例,均接受格卡瑞韦/哌仑他韦治疗8~12周,随访12周。结果两组静脉注射毒品感染HCV的比率分别为60.0%和63.0%;HCV感染者实现持续病毒学应答(SVR)为92.0%,而HIV合并HCV感染者为88.9%,两组间差异无统计学意义(P=1.000);两组患者对该药耐受性良好,均未发生不良事件导致的治疗方案调整或中止。结论应用格卡瑞韦/哌仑他韦治疗HCV感染者和HIV合并HCV感染者具有较好的近期疗效和较高的安全性。Objective This clinical trial was conducted to evaluate the efficacy and safety of glecaprevir/pibrentasvir in treatment of patients with HCV mono-infection and HIV/HCV co-infection.Methods 25 patients with hepatitis C virus infection,including chronic hepatitis C(CHC)in 22 cases and compensated liver cirrhosis(CLC)in 3 cases,and 27 patients with HIV and HCV co-infection,including CHC in 25 cases and CLC in 2 cases,were enrolled in this study between April 2021 and December 2021,and all received glecaprevir/pibrentasvir antiviral therapy for eight to twelve weeks.All patients were followed-up for 12 weeks.Results The percentages of intravenous drug users in the two groups were 60.0%and 63.0%;the sustained virological response(SVR)at 12 weeks after treatment(SVR 12)in patients with HCV infection was 92.0%,not significantly different compared to 88.9%(P=1.000)in patients with HIV/HCV co-infection;the glecaprevir/pibrentasvir therapy was well tolerated in the two groups,and there was no severe adverse events leading to the adjustment or suspension of the anti-viral therapy regimen.Conclusion The administration of glecaprevir/pibrentasvir anti-viral therapy has a promising short-term efficacy and safety in the treatment of patients with HCV mono-infection and HIV/HCV co-infection.

关 键 词：丙型肝炎病毒 艾滋病 混合感染 直接抗病毒药物 格卡瑞韦/哌仑他韦 治疗 安全性 

分 类 号：R512.63[医药卫生—内科学]